Avoid common mistakes on your manuscript.
Dear Reader
As we reach the final issue of the year for Drugs in R&D, we hope that you have found the articles published throughout 2010 to be both interesting and informative. This year saw Drugs in R&D being transformed from subscription based to open access, making it the first Adis journal to embrace the open-access model. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year and were pleased to see a 35% increase in the Drugs in R&D ISI impact factor (IF) to 1.354.
The high quality of other Adis Journals was also recognized in the new ISI IFs for 2009 with ten of our titles making strong IF gains over 2008. The most impressive gains were made by BioDrugs (IF 3.506; up <55%), Drugs (IF 4.732; up <14%), and the American Journal of Clinical Dermatology (IF 1.820; up <17%). The American Journal of Cardiovascular Drugs, a newly tracked journal in 2009, received its first IF (1.964) and was ranked #47 in the ‘Cardiac & Cardiovascular System’ category. Pediatric Drugs was accepted for inclusion in Current Contents/Clinical Medicine and a Thompson ISI IF for the journal is expected in 2013. This year, we also celebrated the 10th anniversary of the American Journal of Clinical Dermatology making significant contributions to the field of dermatology.
We would like to say a big thank you to all the authors who have contributed articles to Drugs in R&D in the last 12 months. Without their hard work and diligence we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals who acted as referees for articles published in Drugs in R&D in 2010:
Omar Ali, USA
Ken Arai, USA
Daniela Bruttomesso, Italy
S. Cai, USA
Si Duanyun, China
Nathalie P. Duroudier, UK
Run-lin Gao, China
Robert Hermann, Germany
Aidan A. Hollis, Canada
Li Hua, China
N. Hunfeld, the Netherlands
W.H. Jost, Germany
S. Karoui, Tunisia
Charanjit Kaur, India
Jennifer Keiser, Switzerland
Miles A. Kirchin, Germany
Ran Kornowski, Israel
Anthony L. Kovac, USA
E. Kul-Panza, Turkey
Shiu K. Lam, China
Alain Lachaux, France
Paul A. Lapchak, USA
Frank R. Lichtenberg, USA
Robert T. Malison, USA
Hiroto Matsuse, Japan
James M. McKenney, USA
Sebastian Muller, France
Ryuichi Ogawa, Japan
Yoshiyuki Ohno, Japan
Hitoshi Osaka, Japan
Brita A. Pekarsky, Australia
Yihong Qiu, USA
Ian Sayers, UK
Dorothea Sesardic, UK
Dirk D. Skowasch, Germany
Takenori Takahata, Japan
Zhiqun Tan, USA
Anna Tavridou, Greece
Henrik S. Thomsen, Denmark
Yoshito Tsushima, Japan
Paul M. Tulkens, Belgium
Yoshiko Unno, Japan
T. Velpandian, India
Liang Xu, USA
T. Yasuda, Japan
We look forward to your continued support and keeping you up-to-date with topical issues in the field of drug research in 2011. With best wishes from the staff of Drugs in R&D and all at Adis, a Wolters Kluwer business.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Acknowledgment. Drugs R D 10, 211–212 (2010). https://doi.org/10.2165/11588100-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11588100-000000000-00000